Documents

DOI

BACKGROUND: Malaria is a leading cause of mortality, particularly in sub-Saharan African children. Prompt and efficacious treatment is important as patients may progress within a few hours to severe and possibly fatal disease. Chlorproguanil-dapsone-artesunate (CDA) was a promising artemisinin-based combination therapy (ACT), but its development was prematurely stopped because of safety concerns secondary to its associated risk of haemolytic anaemia in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. The objective of the study was to assess whether CDA treatment and G6PD deficiency are risk factors for a post-treatment haemoglobin drop in African children
Original languageEnglish
JournalMalaria Journal
Volume11
Issue number139
Pages (from-to)1-7
Number of pages7
ISSN1475-2875
DOIs
Publication statusPublished - 2012

Bibliographical note

ITG-B1B; ITG-B12B; ITG-B13B; ITG-C14B; ITG-BLA; MULTI; DBM; U-MALAR; DCS; U-CTU; JIF; E-only; DOI; PDF; Abstract; DSPACE

    Research areas

  • Protozoal diseases, Malaria, Plasmodium falciparum, Vectors, Mosquitoes, Anopheles, Treatment, Artemisinin combination therapies (ACT), Chlorproguanil, Dapsone, Artesunate, Children, Hemoglobin, Risk factors, G6PD deficiency, Randomized clinical trials, Africa-General, Author, PDF

ID: 264889